



InterGenetics Completes \$6 Million Private Placement

Company Prepares for "OncoVue" Launch and Establishment of National Commercial DNA Diagnostic Facility

For Immediate Release:
May 16, 2005

For More Information Contact:
Jane Braden 405.715.3232

OKLAHOMA CITY—InterGenetics Incorporated, a genetic-based cancer risk testing and treatment company, announced today it has closed a financial transaction with private and institutional investors totaling \$6 million.

“The successful completion of our private placement offering achieves a major milestone and provides the funding to complete our lab diagnostic facility and commercially launch our first cancer risk test for breast cancer called OncoVue,” said Dr. Craig Shimasaki, InterGenetic’s president and CEO. “Furthermore, the successful completion of this offering represents a financial endorsement of the company’s market potential.”

InterGenetics plans to launch OncoVue, the first genetic-based breast cancer risk predictive test able to determine the lifetime and age specific risk for developing breast cancer applicable to all women, this fall. OncoVue is distinguished from other genetic risk assessment tests in that a combination of genes discovered by InterGenetics’ scientists are used to give doctors a picture of a patient’s breast cancer susceptibility which is relevant to all women. OncoVue will give doctors a simple procedure allowing them to tell their patient’s risk of being diagnosed with breast cancer in the future. Doctors can then incorporate this information into their practice to determine the appropriate screening or preventative protocols for their patients.

Dr. Shimasaki reported, "InterGenetics has been preparing for the marketing launch of OncoVue for more than a year. During this time, we have begun development of an expanding Breast Cancer Risk Testing Network around the country that initially will be comprised of 50-60 selected comprehensive breast care centers. The number of centers, will expand to eventually encompass most all of the comprehensive breast care centers around the country to make OncoVue readily available to the 40 million women who get annual mammograms."

The OncoVue test is simple for a woman to perform. First, she completes a brief medical questionnaire. Afterwards she swishes a harmless mouthwash and deposits the fluid into a tube. DNA from the woman's cheek cells is analyzed at InterGenetics' DNA Diagnostic Lab in Oklahoma City along with the data collected from the medical questionnaire to determine a numeric score. The score represents the patient's risk of developing breast cancer every five years of her life.

WilMac Health Partners, a Dallas-based LLC is one of the lead investors in this private placement. "InterGenetics' breast cancer risk test represents a turning point for tools needed to help prevent and detect breast cancer at its earliest stages. ," said Michael McGehee, WilMac Partner. "We believe the company enjoys a competitive advantage in leading the industry into the new medical frontier of genetic-based cancer risk intervention and the investment community is behind them."

"InterGenetics is boldly taking a new science into the medical field,giving physicians and patients better insight into cancer risk so that more can be done to intervene in this terrible disease," commented Bill Swisher, InterGenetics' board member and early investor in the company, . "Finalization of this financing package is an endorsement of the vision, the dedication and creative energy InterGenetics brings to the biotech industry."

Dr. Shimasaki emphasized that while the company is concentrated on the launch in the near term of its OncoVue breast cancer risk test, InterGenetics' research is ongoing and new product developments and product launches are expected to follow the OncoVue launch.

“We are most excited about the progress of our more than ten years of clinical studies to internally validate our science and, every bit as important, the promise our breast cancer predictive test holds to help women live longer, healthier and more vibrant lives,” Dr. Shimasaki concluded.

About InterGenetics

InterGenetics, a genetics-based cancer-risk testing and cancer treatment company is emerging as an innovator in the frontier of genetic medicine. The company's lead product, the OncoVue™ Breast Cancer Risk Test, uses proprietary gene combinations and DNA assessment technology developed by InterGenetics' scientists to quickly and accurately identify women who are at high risk of developing breast cancer, potentially many years in advance of their diagnosis.

InterGenetics has a promising research pipeline of predictive tests for other cancers such as ovarian, colon, prostate, and pancreatic cancer. The company's core research has future application in also predicting heart disease, diabetes and in enhancing the effectiveness of drug therapies and preventative medicine in these fields.

www.intergenetics.com

Forward-Looking Statements

This press release may contain certain “forward-looking” statements within the meaning of the Securities Exchange Act of 1933 and the Securities Exchange Act of 1934. These statements are based on management's current expectations and assumptions and are subject to uncertainty and involve risks, which could materially alter the outcome. Prospective investors are cautioned such forward-looking statements are not guarantees of future performance. The company undertakes no obligation to update or revise forward-looking statements to reflect changed expectations or assumptions to altering future operating results.